OBJECTIVES

  • To enhance the understanding on the burden of alcohol use and alcohol-associated liver disease in the United States
  • To enhance understanding of the concomitant mental health and substance use disorders among patients with alcohol use and alcohol-associated liver disease
  • To bridge the clinical gaps in the alcohol-associated liver disease diagnosis, management and clinical trial design
  • To disseminate the NIAAA-sponsored activities on clinical trials and translational research studies to advance the care and treatment of alcohol-associated liver disease to targeted audience
  • To provide opportunities for graduate students and post-doctoral fellows to network with expert investigators in the area of alcohol use and alcohol-associated liver disease

ORGANIZERS

MEETING DETAILS

Tuesday, Oct 6, 2020 1:00 pm | 2 hours 30 minutes | (UTC-04:00) Eastern Time (US & Canada)

Meeting number: 126 760 8475
Password: grasshopper33
https://nih.webex.com/nih/j.php?MTID=ma668e7338fc7c6a4185b0847fb99f9a7

Join by phone
1-650-479-3208 Call-in toll number (US/Canada)
Access code: 126 760 8475

AGENDA

ZOOM session
Moderators: Laura E Nagy, PhD, Cleveland Clinic and Suthat Liangpunsakul, MD, Indiana University, IN
Format: 30 min per speaker (~22 min presentation and 8 min Q&A)

1:00pm     
 
Opening remarks  

 

George Koob, PhD, NIAAA Director  
 
1:05pm  
 
Pathogenesis and mechanism of alcohol-associated liver disease – pave the way to therapeutic targets
Inflammation or impaired regeneration: which pathways are important for treatment?  
 
Anna Mae Diehl, MD  

 

1:35pm  
 
From bench to bedside - Disease Definitions and clinical studies AH
Clinical trials in patients with AH – based on disease severity – inclusion and exclusion criteria, endpoints, duration, and confounders.  
 
Mack Mitchell, MD  

 

2:05pm  
 
Clinical studies and the use of biomarkers in the real world, obstacles and challenge: Insights from the design and implementation of medications development trials for alcohol use disorder.  
 
Mark Thursz, MD  

 

2:35pm  

 

Clinical Addiction perspective –
How to address AUD and substance abuse disorder in patients with alcohol-associated liver disease: behavioral and pharmacological intervention?  
 
Lorenzo Leggio, MD, PhD  

 

3:05pm  
 
Liver transplantation in patients with alcohol-associated liver disease
Preventing relapse after liver transplant: “app” based support.  
 
Betsy McCaul, PhD